Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection
- PMID: 32500556
- PMCID: PMC7301006
- DOI: 10.1111/ejh.13460
Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection
Conflict of interest statement
We declare no competing interests.
Comment on
-
COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.Eur J Haematol. 2020 Sep;105(3):357-359. doi: 10.1111/ejh.13432. Epub 2020 May 7. Eur J Haematol. 2020. PMID: 32324284 Free PMC article.
References
-
- FDA cautions against use of hydroxychloroquine or chloroquine for COVID‐19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. (online) https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐cautions‐agai.... Accessed May 2, 2020.
-
- Commons RJ, Simpson JA, Thriemer K, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta‐analysis. BMC Med. 2019;17:151. - PMC - PubMed
-
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1‐26. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
